fluzoparib + dalpiciclib + fulvestrant

This combination therapy consists of **fluzoparib**, a poly (ADP-ribose) polymerase (PARP) inhibitor, **dalpiciclib**, a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, and endocrine therapy, typically **fulvestrant** or an aromatase inhibitor. Developed by **Jiangsu Hengrui Pharmaceuticals**, this triplet regimen is currently being evaluated in a Phase III clinical trial (NCT05362409) led by investigator **Zhimin Shao** for the first-line treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. The study specifically targets the **SNF3 molecular subtype**, a classification identified by Shao's team that may benefit from the synergistic inhibition of DNA repair mechanisms, cell cycle progression, and estrogen receptor signaling to overcome resistance to standard-of-care treatments.

Brand names

AiRuiZhiAiRuiYiFaslodex

Other names

fluzoparib + dalpiciclib + endocrine therapySHR-3162 + SHR6390 + fulvestrant